Lurasidone Adjunctive to Lithium or Divalproex for Bipolarity type I
This study is completed in the United States, in Australia, in France, .... It is testing lurasidone Adjunctive to Lithium or Divalproex for Bipolarity type I.
BipolarityDrugOver 18 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Lurasidone Adjunctive may be useful for adults experiencing bipolarity.
What would participation involve?
Participants may receive Lurasidone Adjunctive, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Argentina, in Australia, and in Bulgaria.
Who is it mainly for?
This study appears to be mainly for adults with bipolarity.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateJune 2011
Recruitment status
Completed
Enrollment listed in the registry
965
Sponsor
Sumitomo Pharma America, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Australia, France, ...
Age range
Over 18 Years
Official registry ID
NCT01358357
Official title
A Randomized, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects With Bipolar I Disorder
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
State Healthcare and Forensic Psychiatric Expertise Institution
Izhevsk
Site status: Not listed — confirm with the team
Nizhny Novgorod Regional State Institution of Healthcare
Nizhny Novgorod
Site status: Not listed — confirm with the team
St. Petersburg State Healthcare Institution (SPSHI)
Saint Petersburg
Site status: Not listed — confirm with the team
St.Petersburg State Healthcare Institution (SPSHI)
Saint Petersburg
Site status: Not listed — confirm with the team
St Petersburg State Government Healthcare Institution
Saint Petersburg
Site status: Not listed — confirm with the team
Mental Health Research Institute of Rams
Tomsk
Site status: Not listed — confirm with the team
Serbia · 5 sites
Clinical Centre of Serbia
Belgrade
Site status: Not listed — confirm with the team
Clinical Hospital Centre Dragisa Misovic
Belgrade
Site status: Not listed — confirm with the team
Psychiatric Clinic Clinical Center Kragujevac
Kragujevac
Site status: Not listed — confirm with the team
Clinical Centre Nis
Niš
Site status: Not listed — confirm with the team
Specialized Hospital for Psychiatric Diseased "Sveti Vracevi"
Novi Kneževac
Site status: Not listed — confirm with the team
Slovakia · 2 sites
Vseobecna Nemocnica Rimavska Sobota, NaP, n.o. Bratislava
Rimavská Sobota
Site status: Not listed — confirm with the team
Psychiatricka ambulancia
Zlaté Moravce
Site status: Not listed — confirm with the team
United States · 26 sites
Harmonex Neuroscience Research
Dothan, Alabama
Site status: Not listed — confirm with the team
Behavioral Research Specialists, LLC
Glendale, California
Site status: Not listed — confirm with the team
AXIS Clinical Trials
Los Angeles, California
Site status: Not listed — confirm with the team
Excell Research, Inc.
Oceanside, California
Site status: Not listed — confirm with the team
Stanford University School of Medicine Research Program VA Palo Alto Health Care System
Palo Alto, California
Site status: Not listed — confirm with the team
SF-CARE, Inc.
San Francisco, California
Site status: Not listed — confirm with the team
Neuropsychiatric Research Center of Orange County
Santa Ana, California
Site status: Not listed — confirm with the team
"Stanford University School of Medicine
Stanford, California
Site status: Not listed — confirm with the team
Florida Clinical Research LLC
Bradenton, Florida
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Site status: Not listed — confirm with the team
Galiz Research
Miami Springs, Florida
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions
Orlando, Florida
Site status: Not listed — confirm with the team
Atlanta Center for Medical Research
Atlanta, Georgia
Site status: Not listed — confirm with the team
Clinco
Terre Haute, Indiana
Site status: Not listed — confirm with the team
ActivMed Practices & Research Inc.
Haverhill, Massachusetts
Site status: Not listed — confirm with the team
Psych Care Consultants Research
St Louis, Missouri
Site status: Not listed — confirm with the team
Village Clinical Research Inc,
New York, New York
Site status: Not listed — confirm with the team
Finger Lakes Clinical Research
Rochester, New York
Site status: Not listed — confirm with the team
Charak Center for Health and Wellness
Garfield Heights, Ohio
Site status: Not listed — confirm with the team
Cutting Edge Research Groupd
Oklahoma City, Oklahoma
Site status: Not listed — confirm with the team
Suburban Research Associates
Media, Pennsylvania
Site status: Not listed — confirm with the team
Lincoln Research
Lincoln, Rhode Island
Site status: Not listed — confirm with the team
Carolina Clinical Trials, Inc.
Charleston, South Carolina
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions Inc.
Memphis, Tennessee
Site status: Not listed — confirm with the team
Psychoneuroendocrinology Research Group, Dept of Psychiatry, UT Southwestern Medical Center
Dallas, Texas
Site status: Not listed — confirm with the team
R/D Clinical Research, Inc.
Lake Jackson, Texas
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT01358357. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Lurasidone, Placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with bipolarity; age range: Over 18 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Sumitomo Pharma America, Inc., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
